Neutrophil myeloperoxidase as a functional biomarker for RSV severity: implications for in vitro therapeutic screening.

This study identifies neutrophil myeloperoxidase (MPO) as a critical biomarker for RSV severity and demonstrates its utility as a functional readout in a physiologically relevant in vitro model to screen therapeutics that effectively reduce neutrophil-driven inflammation.

The Gist

The Big Picture: A Viral Storm in the Lungs

Imagine a baby's lungs as a busy, delicate city. RSV (Respiratory Syncytial Virus) is like a chaotic storm that crashes into this city, causing panic and damage. While the city's security guards (the immune system) rush in to fight the storm, sometimes they get too excited. They start throwing too much debris, damaging the city's own buildings (the lung tissue) in the process. This overreaction is what makes the illness so severe in babies.

Currently, doctors have very few tools to stop this storm or calm down the security guards. This study is like a team of scientists building a miniature, high-tech model city in a lab to figure out how to stop the damage and test new ways to save the city.

---

1. The "Smoke Alarm" of the Body: Myeloperoxidase (MPO)

The researchers first looked at real babies in the hospital who were very sick with RSV. They found a specific chemical marker called Myeloperoxidase (MPO).

• The Analogy: Think of MPO as a smoke alarm that is screaming at maximum volume.
• The Discovery: In healthy babies, the alarm is quiet. In babies with severe RSV, the alarm is blaring. The researchers realized that the louder the alarm (the higher the MPO levels), the more damage the "security guards" (neutrophils) were doing to the lungs.
• Why it matters: They decided that measuring this "alarm" is a perfect way to tell how sick a baby is and, more importantly, to see if a new medicine is working to turn the alarm down.

2. Building the "Mini-City" in a Lab

To test medicines without hurting real babies, the scientists built a 3D model of a baby's airway.

• The Setup: Imagine a sandwich.
  • The Bread (Top): A layer of baby lung cells (epithelial cells).
  • The Filling (Middle): A layer of blood vessel cells (endothelial cells).
  • The Bottom: A space where they can add the "security guards" (neutrophils).
• The Magic: They infected this mini-city with RSV. They watched what happened when the security guards tried to cross the "border" (the blood vessel and lung lining) to get to the virus.
• The Finding: They discovered that the baby's lung cells are like super-charged magnets. When RSV hits them, they scream for help louder than adult lungs do. This causes the security guards to rush in faster and get "angrier" (more activated), releasing more of that "smoke alarm" chemical (MPO).

3. Testing the Firefighters: Two New Medicines

The scientists tested two different "firefighters" (antiviral drugs) to see which one could stop the storm and calm the guards.

• Firefighter A (Remdesivir): This is a broad-spectrum drug. It's good at stopping the virus from multiplying.
  • Result: It stopped the virus (the storm), but the security guards were still a bit agitated and kept throwing debris. It reduced the virus, but didn't fully calm the panic.
• Firefighter B (RSV604): This is a drug specifically designed to stop RSV.
  • Result: It stopped the virus and it did something amazing: it calmed the security guards. The guards still rushed in to help, but they didn't get as angry. They threw less debris, and the "smoke alarm" (MPO) went down significantly.

4. The "Direct Contact" Secret

The researchers also figured out why the guards get so angry. They found that the guards don't just get angry because of chemicals floating in the air. They get angry because they physically touch the virus-infected lung cells.

• The Analogy: It's like a security guard getting angry only when they shake hands with a rioter. If they just stand on the other side of a fence and hear shouting, they stay calm. But once they cross the fence and touch the rioter, they go into "attack mode."
• The Lesson: To stop the damage, we need to stop that physical contact or calm the guards down while they are fighting.

The Takeaway: What Does This Mean for the Future?

This study is a big step forward for two reasons:

1. A New Compass: The "smoke alarm" (MPO) is now a proven tool. If a new drug can turn down the MPO alarm in the lab, it's a strong sign that the drug will help real babies by reducing lung damage.
2. A New Strategy: It suggests that the best treatment for severe RSV isn't just killing the virus; it's also about calming the immune system's overreaction. The drug RSV604 showed promise in doing both: killing the virus and keeping the "security guards" from destroying the city.

In short: The scientists built a tiny, perfect model of a baby's lung to prove that we need to stop the "smoke alarm" (MPO) to save the baby. They found a drug that does exactly that, offering hope for a better treatment for RSV in the future.

Technical Summary

1. Problem Statement

Respiratory Syncytial Virus (RSV) is a leading cause of severe lower respiratory tract infections in infants, resulting in significant hospitalizations and mortality. Despite the high disease burden, there are no routinely used, effective antiviral therapeutics for immunocompetent children. Current treatments are limited to prophylaxis (monoclonal antibodies) or symptom management.

A critical gap in drug development is the lack of predictive in vitro models that accurately recapitulate the complex immune pathology of infant RSV bronchiolitis. Specifically, the role of neutrophil activation and the difficulty in quantifying this response in clinical trials hinder the identification of effective therapeutics. The study aims to develop a physiologically relevant in vitro model to identify biomarkers of severity (specifically neutrophil degranulation) and screen antiviral candidates based on their ability to modulate this inflammatory response.

2. Methodology

The study employed a multi-stage approach combining clinical sample analysis with advanced in vitro modeling:

• Clinical Cohort & Sample Collection:

  • Peripheral blood neutrophils were isolated from infants admitted to the Paediatric Intensive Care Unit (PICU) with RSV infection ($n=5$) and uninfected control PICU patients ($n=5$).
  • Healthy adult neutrophils ($n=15$) served as a comparative baseline.
  • Samples were analyzed via flow cytometry for activation markers (CD11b, CD64, CD62L) and degranulation markers (Myeloperoxidase [MPO], Neutrophil Elastase [NE]).
  • Transcriptomic profiling (Oxford Nanopore sequencing) was performed on purified neutrophils to identify gene expression signatures.

• In Vitro Model Development:

  • Air-Liquid Interface (ALI) Cultures: Primary airway epithelial cells (AECs) from both children (0–4 years) and adults were differentiated at the ALI for 28 days.
  • Co-culture System: To enhance physiological relevance, a vascular endothelial cell (EC) layer was added to the basolateral side of the AECs, creating a blood-airway barrier model.
  • Infection & Migration: Cultures were infected with GFP-tagged RSV (MOI 1). Purified neutrophils were introduced to the basolateral side to assess trans-epithelial migration.
  • Barrier Integrity: Assessed via Transepithelial Electrical Resistance (TEER) and Dextran permeability assays.

• Therapeutic Screening:

  • Two antiviral candidates were tested: Remdesivir (RDV) (broad-spectrum nucleoside analogue) and RSV604 (small-molecule fusion inhibitor).
  • Drugs were applied 4 hours post-infection.
  • Outcomes measured included viral load (RT-qPCR), cytokine secretion (IL-6, IL-8, IP-10), and neutrophil phenotypic changes (flow cytometry and enzymatic activity assays for MPO/NE).

• Statistical Analysis:

  • Data were normalized to "medium-only" controls to account for donor variability.
  • Quartile scoring and radar charts were used to visualize multi-marker expression patterns.
  • Transcriptomics utilized edgeR for differential expression and Gene Ontology (GO) enrichment analysis.

3. Key Contributions

• Identification of MPO as a Severity Biomarker: The study establishes Myeloperoxidase (MPO) as a specific, quantifiable marker of RSV disease severity in infants, distinguishing severe cases from controls more effectively than other surface markers.
• Physiologically Relevant Pediatric Model: The development of a pediatric ALI model incorporating an endothelial layer successfully recapitulates the in vivo environment, demonstrating that pediatric epithelium drives stronger neutrophil recruitment and specific degranulation patterns compared to adult epithelium.
• Mechanistic Insight into Neutrophil Activation: The study proves that neutrophil degranulation (specifically MPO/NE upregulation) is dependent on direct contact with RSV-infected epithelial cells rather than soluble factors alone.
• Novel Therapeutic Screening Endpoint: The paper proposes that antiviral efficacy should not be judged solely by viral load reduction but must also include the modulation of neutrophil-driven inflammation (specifically MPO reduction) to prevent tissue damage.

4. Key Results

• Clinical Findings:

  • RSV-infected infants had significantly lower circulating neutrophil counts (indicating tissue recruitment) but significantly higher expression of MPO and NE compared to age-matched controls.
  • Transcriptomics revealed a distinct infection-associated transcriptional program in RSV neutrophils, with strong correlation between ELANE (NE) and MPO genes.

• Model Validation:

  • Age Dependency: Pediatric AECs induced significantly higher neutrophil migration and MPO expression compared to adult AECs.
  • Endothelial Impact: Adding an endothelial layer preserved barrier integrity and enhanced the physiological response. ECs increased cytokine production (IL-6, IL-8) and significantly boosted neutrophil migration and MPO/NE expression in the basolateral compartment.
  • Contact Dependence: Using transwell inserts with blocked pores (0.4 µm) vs. permissive pores (3.0 µm), the study confirmed that high MPO/NE expression in basolateral neutrophils requires direct migration and contact with infected epithelium, not just soluble cytokines.

• Therapeutic Screening:

  • Viral Load: Both Remdesivir and RSV604 effectively reduced RSV viral load and GFP fluorescence.
  • Inflammatory Modulation:
    • Remdesivir: Reduced viral load but failed to attenuate neutrophil activation markers (MPO/NE) or inflammatory cytokines; in some cases, it did not reduce IL-6/IP-10 levels.
    • RSV604: While also reducing viral load, RSV604 uniquely attenuated MPO expression and enzymatic activity. It promoted the migration of viable neutrophils that exhibited a "less activated" phenotype (lower MPO/NE/CD11b) compared to the untreated RSV group.

5. Significance

This study fundamentally shifts the paradigm for RSV therapeutic development by highlighting that reducing viral load alone is insufficient if the drug does not mitigate the host's pathological inflammatory response.

• Biomarker Utility: MPO is validated as a robust biomarker for disease severity and a functional readout for drug efficacy.
• Drug Differentiation: The study demonstrates that RSV604 may offer a superior therapeutic profile compared to Remdesivir in the context of infant RSV, as it targets the virus while simultaneously dampening the neutrophil-mediated tissue damage that drives severe bronchiolitis.
• Future Screening: The proposed in vitro model, which integrates pediatric epithelium, endothelium, and neutrophils, provides a critical platform for pre-clinical screening of antivirals that aim to balance viral clearance with the preservation of airway integrity.

The authors conclude that future antiviral discovery for RSV must prioritize the reduction of neutrophil-driven inflammation (specifically MPO) alongside viral suppression to effectively treat severe infant infections.